In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report), with a price target of $26.00. The company’s shares closed yesterday at $9.47.
Catanzaro covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Gilead Sciences, and Iovance Biotherapeutics. According to TipRanks, Catanzaro has an average return of 9.7% and a 41.18% success rate on recommended stocks.
Currently, the analyst consensus on Acrivon Therapeutics, Inc. is a Strong Buy with an average price target of $20.71, an 118.69% upside from current levels. In a report released on April 10, JonesTrading also maintained a Buy rating on the stock with a $26.00 price target.
The company has a one-year high of $14.30 and a one-year low of $3.19. Currently, Acrivon Therapeutics, Inc. has an average volume of 725.2K.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACRV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acrivon Therapeutics, Inc. (ACRV) Company Description:
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Read More on ACRV:
- Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- Acrivon Therapeutics presents data at AACR meeting
- Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Acrivon Therapeutics Secures $130M for Drug Development Expansion
- Acrivon to sell 8.24M shares at $8.50 in private placement financing
